ARDELYX INC. - COMMON STOCK

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

28 9 2023 07:02:00 提供 Nasdaq GlobeNewswire

Tenapanor for Hyperphosphatemia Approved in Japan

25 9 2023 03:15:13 提供 Nasdaq GlobeNewswire

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023

11 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference

08 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

07 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance

02 8 2023 06:00:00 提供 Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

27 7 2023 15:05:00 提供 Nasdaq GlobeNewswire

Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023

26 7 2023 06:55:00 提供 Nasdaq GlobeNewswire

Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference

20 7 2023 15:05:00 提供 Nasdaq GlobeNewswire

Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

13 7 2023 07:00:01 提供 Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

29 6 2023 15:09:08 提供 Nasdaq GlobeNewswire

Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase

05 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

Ardelyx to Present at the Jefferies 2023 Healthcare Conference

31 5 2023 07:00:00 提供 Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

23 5 2023 15:05:00 提供 Nasdaq GlobeNewswire

Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)

17 5 2023 06:30:00 提供 Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

15 5 2023 15:05:01 提供 Nasdaq GlobeNewswire

Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

09 5 2023 07:00:02 提供 Nasdaq GlobeNewswire

Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update

03 5 2023 15:02:00 提供 Nasdaq GlobeNewswire

Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference

01 5 2023 07:00:01 提供 Nasdaq GlobeNewswire

Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

26 4 2023 07:00:01 提供 Nasdaq GlobeNewswire